<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73767">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774643</url>
  </required_header>
  <id_info>
    <org_study_id>XENO-METPANC</org_study_id>
    <nct_id>NCT01774643</nct_id>
  </id_info>
  <brief_title>A Study of Pancreatic Cancer in Xenografts From Liver Metastases</brief_title>
  <official_title>A Feasibility Study Of Developing Murine Primary Xenografts From Biopsies Of Liver Metastases In Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to perform image-guided liver biopsies in 25 patients who have
      pancreatic cancer with liver metastasis (cancer in the pancreas that has spread to the
      liver). This will contribute with samples for the bio-bank (bank of tumors) and develop
      xenografts (human tumors growing in mice) for further analysis of genes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study might bring a better understanding of the metastatic pancreatic cancer and
      evaluate the differences between the metastatic and the primary pancreatic cancer (the type
      that does not have metastasis).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of patients with adverse events due to biopsies</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of successful xenografts</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of similiarities and differences between original patient tumor sample with xenograft sample</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Tumor Tissue Biopsy</condition>
  <condition>Blood Samples</condition>
  <arm_group>
    <arm_group_label>Pancreatic cancer with liver metastases</arm_group_label>
    <description>Tumor tissue biopsy, blood samples</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pancreatic cancer patients with liver metastases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age of 18 years old

          -  Pancreatic cancer with liver metastasis

          -  No contraindication to image-guided biopsy of liver metastasis, including
             uncontrolled bleeding diathesis, uncontrolled malignant pain, inability to lie supine
             etc) and no significant hepatic dysfunction.

          -  Provide written informed consent

          -  ECOG 0,1 or 2

        Exclusion Criteria:

          -  Inability to lie supine for more than 30 minutes

          -  ECOG 3 or more

          -  Serious medical risk factors involving any of the major organ systems or including
             uncontrolled bleeding diathesis, uncontrolled malignant pain, inability to lie supine
             etc) and no significant hepatic dysfunction.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moore Malcolm, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ria Sayat</last_name>
    <email>ria.sayat@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Malcolm J. Moore, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neesha Dhani, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 22, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Tumor tissue biopsy</keyword>
  <keyword>Blood samples</keyword>
  <keyword>Xenografts</keyword>
  <keyword>Murine</keyword>
  <keyword>Genomic profiling</keyword>
  <keyword>Circulating biomarkers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
